5

20

25

CLAIMS

1. Compound characterized in that it corresponds to formula (1)

$$H_2N$$
 R_3
 R_1
 R_3
 R_4
 R_4
 R_5
 R_4
 R_5
 R_5
 R_7
 R_8
 R_8
 R_8

in which

• each group R^1 is identical to the other group R^1 and represents:

10 - a C_1 to C_6 alkyl, C_2 to C_6 alkenyl or C_2 to C_6 alkynyl group,

- a $(CH_2)_n$ benzyl group in which n is equal to 0 or 1,

- a $(CH_2)_m(C_3$ to C_6 cycloalkyl) group in which m is equal to 0 or 1,

each of the alkyl, alkenyl, alkynyl, benzyl or cycloalkyl groups being substituted with one or two group(s) represented by the group A;

• the group A represents:

- a carboxylate group COOH or COOR, R representing a C_1 to C_6 alkyl or CH_2 phenyl group;

- a sulfonate group SO_3H or SO_3R' , R' representing a C_1 to C_6 alkyl or CH_2 phenyl group;

- a phosphonate group PO_3H_2 or $PO_3R_2"R'"$, R'' and R'" independently representing H, or a C_1 to C_6 alkyl or CH_2 phenyl group;

- each group R^2 is identical to the other group R^2 and represents a C_1 to C_6 alkyl, C_2 to C_6 alkenyl or C_2 to C_6 alkynyl group, each alkyl, alkenyl or alkynyl group being free or substituted with the group B;
- the group B represents:

- a carboxylate group, COOH or COOR', R' representing a C₁ to C₆ alkyl or CH₂phenyl group;
- a phenyl group that is free or substituted with one or more radicals chosen from a halogen atom, an optionally protected hydroxyl radical, a C_1 to C_4 alkyl group, a cyano group, a free, salified or esterified carboxyl group or an amide group;
- each group R^3 is identical to the other group R^3 and represents a hydrogen atom.
- 2. Compound according to Claim 1, characterized in that R^1 is chosen from C_1 to C_6 alkyl, C_2 to C_6 alkenyl and benzyl groups, each of these groups being substituted with one or two group(s) represented by the group A as defined in Claim 1.

5

25

35

- 3. Compound according to either of Claims 1 and 2, characterized in that R^2 is chosen from a C_1 to C_6 alkyl group and a C_2 to C_6 alkenyl group, it being possible for each of these groups to be substituted with one or two group(s) represented by the group B as defined in Claim 1.
 - 4. Compound according to any one of Claims 1 to 3, characterized in that R^1 represents an ethyl group substituted with a sulfonic group, a phosphonic group or a carboxylic group, that is free, salified or esterified, and R^2 represents an ethyl group substituted with a free or substituted phenyl group.
 - 5. Compound according to any one of Claims 1 to 4, characterized in that it is 4.4'-dithiobis-(3.3'-amino-6.6'-phenyl-1.1'-hexanesulfonic) acid.
- 6. Compound according to Claim 5, characterized in that it is 4(S), 4'(S), 3(S), 3'(S) 4' dithiobis (3, 3' amino 6, 6' phenyl 1, 1' hexane sulfonic) acid.
 - 7. Compound according to any one of Claims 1 to 6, characterized in that it is for use in therapeutics.
 - 8. Pharmaceutical composition, characterized in

that it comprises a compound according to any one of Claims 1 to 6.

9. Use of a compound according to any one of Claims 1 to 6, as a selective inhibitor with regard to aminopeptidase A.

5

- 10. Use of a compound according to any one of Claims 1 to 6, for preparing a medicinal product for use in the treatment of arterial hypertension and of directly and indirectly related diseases.
- 10 Use of a compound according to any one of Claims 1 to 6, for preparing a medicinal product for use in the treatment of a disease chosen from primary or secondary arterial hypertension, an ictus, myocardial ischemia, cardiac insufficiency and renal insufficiency, 15 infarction, a peripheral vascular disease, myocardial diabetic protinuria, syndrome Χ, glaucoma, neurodegenerative diseases and memory disorders.
- 12. Use of a compound according to any one of Claims 1 to 6, for preparing a medicinal product for use in the treatment of ischemic and tumoral pathologies in which aminopeptidase A is involved.